文献速递药物不良反应与药物警戒

药师对处方错误的干预:住院环境下标准化方法的应用

Pharmacist intervention on prescribing errors: Use of a standardized approach in the inpatient setting.
PubMed 文献 · Am J Health Syst Pharm · 2021-01-01

这项前瞻性多中心观察研究在11家医院连续6周采用标准化记录流程,收集住院医嘱审核中药师拦截的处方错误,并用改良NCC-MERP指数由医生验证潜在危害。药师共干预7187个错误,平均错误率为每1000患者日39个,其中46.6%可能造成严重后果、2.4%可能危及生命,避免费用874000美元。

要点

  • 药师拦截的处方错误中46.6%可能造成严重后果,2.4%可能危及生命。
  • 最高频错误类型为剂量/速率/频次错误(32.0%)、重复治疗(19.9%)、给药时机错误(13.4%)。
  • 标准化记录流程支持多中心分析处方错误趋势并推动系统级改进。

核心结论

  • 通过标准化流程记录药师对处方错误的干预,可为多中心分析处方错误趋势和制定系统级解决方案提供平台。

研究设计与样本

  • 前瞻性、多中心、观察性研究,在11家医院连续6周对住院医嘱审核中药师拦截的处方错误进行标准化记录。
  • 使用改良NCC-MERP指数由医生验证评估每个错误的潜在危害,并分为潜在低危害、严重危害或危及生命。

主要发现

  • 药师共干预7187个错误,平均错误率为每1000患者日39个错误。
  • 46.6%(n=3349)的错误可能造成严重后果,2.4%(n=175)若未拦截可能危及生命,避免费用874000美元。
  • 最高频错误类型为剂量/速率/频次错误(n=2298,32.0%)、重复治疗(n=1431,19.9%)、给药时机错误(n=960,13.4%)。
  • 在可能危及生命的错误中,剂量/速率/频次错误(n=49,28%)、重复治疗(n=26,14.9%)、药物-疾病相互作用(n=24,13.7%)频率最高。
  • 在可能造成严重危害的错误中,剂量/速率/频次错误(n=1028,30.7%)、给药时机错误(n=573,17.1%)、重复治疗(n=482,14.4%)频率最高。

临床怎么用

  • 临床药师可参考标准化记录流程对处方错误进行拦截和分类,重点关注剂量/速率/频次、重复治疗和给药时机错误。
  • 对可能危及生命的错误类型(如药物-疾病相互作用)应加强审核与干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study was to implement a standardized process across health systems to determine the prevalence and clinical relevance of prescribing errors intercepted by pharmacists. METHODS: This prospective, multicenter, observational study was conducted across 11 hospitals. Pharmacist-intercepted prescribing errors were collected during inpatient order verification over 6 consecutive weeks utilizing a standardized documentation process. The potential harm of each error was evaluated using a modified National Coordinating Council for Medication Error Reporting and Prevention (NCC-MERP) index with physician validation, and errors were stratified into those with potentially low, serious, or life-threatening harm. Endpoints included the median error rate per 1,000 patient days, error type, and potential harm with correlating cost avoidance. RESULTS: Pharmacists intervened on 7,187 errors, resulting in a mean error rate of 39 errors per 1,000 patient days. Among the errors, 46.6% (n = 3,349) were determined to have potentially serious consequences and 2.4% (n = 175) could have been life-threatening if not intercepted. This equates to $874,000 in avoided cost. The top 3 error types occurring with the highest frequency were "wrong dose/rate/frequency" (n = 2,298, 32.0%), "duplicate therapy" (n = 1,431, 19.9%), and "wrong timing" (n = 960, 13.4%). "Wrong dose/rate/frequency" (n = 49, 28%), "duplicate therapy" (n = 26, 14.9%), and "drug-disease interaction" (n = 24, 13.7%) errors occurred with the highest frequency among errors with potential for life-threatening harm. "Wrong dose/rate/frequency" (n = 1,028, 30.7%), "wrong timing" (n = 573, 17.1%), and "duplicate therapy" (n = 482, 14.4%) errors occurred with the highest frequency among errors with potentially serious harm. CONCLUSION: Documentation of pharmacist intervention on prescribing errors via a standardized process creates a platform for multicenter analysis of prescribing error trends and an opportunity for development of system-wide solutions to reduce potential harm from prescribing errors.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Cabri A, Barsegyan N, Postelnick M, et al. Pharmacist intervention on prescribing errors: Use of a standardized approach in the inpatient setting. Am J Health Syst Pharm. 2021. PMID: 34283219. doi:10.1093/ajhp/zxab278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。